Overall Survival
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
Michiaki Unno, Fuyuhiko Motoi, Yutaka Matsuyama, Sohei Satoi, Hirochika Toyama, Ippei Matsumoto, Suefumi Aosasa, Hirofumi Shirakawa, Keita Wada, Tsutomu Fujii, Hideyuki Yoshitomi, Shinichiro Takahashi, Masayuki Sho, Hideki Ueno, Tomoo Kosuge
Ann Surg 283(1) 57-64
OBJECTIVE: This randomized phase II/III study evaluated the superiority of neoadjuvant therapy with gemcitabine plus S-1 over upfront surgery for patients with resectable pancreatic ductal adenocarcinoma (PDAC). BACKGROUND: PDAC is a leading cause of cancer mortality that urgently requires better treatment. METHODS: Patients with resectable PDAC (without arterial abutment) were randomly assigned to upfront surgery or neoadjuvant chemotherapy with gemcitabine (1000 mg/m 2 days 1 and 8) and S-1 (40-60 mg orally twice daily, days 1-14 every 3 wk for 2 cycles). Phase II and III primary endpoints were resection rate and overall survival, respectively. UMIN Clinical Trials Registry number: UMIN000009634. RESULTS: Patients (n=364) were enrolled and randomly allocated to upfront surgery (UPS; n=182) or neoadjuvant gemcitabine plus S-1 (NAC-GS; n=182). Patient demographics and tumor characteristics were balanced between groups. Median overall survival in the UPS and NAC-GS groups was 26.6 (95% CI: 21.5, 31.5) and 37.0 (95% CI: 28.6, 43.3) months, respectively. The hazard ratio for mortality in the NAC-GS group compared with the UPS group was 0.73 (95% CI: 0.56, 0.95; P =0.018). Median relapse-free survival in the UPS and NAC-GS groups was 11.3 (95% CI: 9.41, 13.5) and 14.3 (95% CI: 11.7, 17.0) months, respectively. The hazard ratio for relapse in the NAC-GS group compared with the UPS group was 0.77 (95% CI: 0.61, 0.98; P =0.030). CONCLUSIONS: The Prep-02/JSAP05 trial results showed that neoadjuvant chemotherapy with gemcitabine plus S-1 significantly extends survival compared with upfront surgery in patients with resectable PDAC.
1 个 Figure · 2 个 KM 面板
FIGURE 2 Kaplan-Meier survival curves. A, Overall survival. Median overall survival was 26.6 months (95% CI: 21.5, 31.5) in the UPS group and 37.0 months (95% CI: 28.6, 43.3) in the NAC-GS group. The hazard ratio for mortality in the NAC-GS group compared with the UPS group was 0.73 (95% CI: 0.56, 0.95, P =0.018). B, Relapse-free survival. Median relapse-free survival was 11.3 months (95% CI: 9.4, 13.5) in the UPS group and 14.3 (95% CI: 11.7, 17.0) in the NAC-GS group. The hazard ratio for relapse in the NAC-GS group compared with the UPS group was 0.77 (95% CI: 0.61, 0.98, P =0.030).
FIGURE 2 · Panel A
Panel A 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
FIGURE 2 · Panel B
Panel B 是同一 FIGURE 2 中的独立 KM 子图;人群、终点或分析条件以本 Panel 图注语义为准。
这些图片未产生 KM 曲线结果,不在主页面重复展示。